CL2019002155A1 - Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas. - Google Patents

Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas.

Info

Publication number
CL2019002155A1
CL2019002155A1 CL2019002155A CL2019002155A CL2019002155A1 CL 2019002155 A1 CL2019002155 A1 CL 2019002155A1 CL 2019002155 A CL2019002155 A CL 2019002155A CL 2019002155 A CL2019002155 A CL 2019002155A CL 2019002155 A1 CL2019002155 A1 CL 2019002155A1
Authority
CL
Chile
Prior art keywords
fusion proteins
factor
procedures
preparation
fix
Prior art date
Application number
CL2019002155A
Other languages
English (en)
Inventor
Robert T Peters
John Kulman
Der Flier Arjan Van
Zhiqian Liu
David R Light
Ekta Seth Chhabra
Tongyao Liu
Ayman Ismail
Original Assignee
Bioverativ Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Therapeutics Inc filed Critical Bioverativ Therapeutics Inc
Publication of CL2019002155A1 publication Critical patent/CL2019002155A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA PRESENTE DESCRIPCIÓN PROPORCIONA PROTEÍNAS DE FUSIÓN DEL FACTOR IX (FIX) QUE COMPRENDEN AL MENOS UN RESTO HETERÓLOGO, TAL COMO UN XTEN. LA PRESENTE DESCRIPCIÓN DESCRIBE ADEMÁS MÉTODOS PARA PREPARAR Y UTILIZAR LAS PROTEÍNAS DE FUSIÓN DEL FIX.
CL2019002155A 2017-01-31 2019-07-31 Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas. CL2019002155A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762452826P 2017-01-31 2017-01-31

Publications (1)

Publication Number Publication Date
CL2019002155A1 true CL2019002155A1 (es) 2020-02-21

Family

ID=61193175

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002155A CL2019002155A1 (es) 2017-01-31 2019-07-31 Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas.

Country Status (19)

Country Link
US (1) US20210238259A1 (es)
EP (1) EP3576762A1 (es)
JP (1) JP2020505424A (es)
KR (1) KR20190112763A (es)
CN (1) CN110831613A (es)
AR (1) AR110871A1 (es)
AU (1) AU2018215092A1 (es)
BR (1) BR112019015569A2 (es)
CA (1) CA3051862A1 (es)
CL (1) CL2019002155A1 (es)
CR (1) CR20190389A (es)
EA (1) EA201991768A1 (es)
IL (1) IL268234A (es)
MA (1) MA47416A (es)
MX (1) MX2019009063A (es)
PH (1) PH12019501765A1 (es)
SG (1) SG11201906788XA (es)
TW (1) TW201831521A (es)
WO (1) WO2018144623A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112175088B (zh) * 2019-07-02 2023-03-28 江苏晟斯生物制药有限公司 改进的fix融合蛋白、缀合物及其应用
CN113817759B (zh) * 2020-07-10 2023-06-02 南京吉迈生物技术有限公司 修饰的因子ix、组合物、方法及其在基因治疗中的应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
ATE74164T1 (de) 1985-04-22 1992-04-15 Genetics Inst Herstellung mit hoher leistung des aktivfaktors ix.
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
JP3045539B2 (ja) 1989-02-21 2000-05-29 ワシントン ユニバーシティ 改変型生殖ホルモン
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
WO1992016221A1 (en) 1991-03-15 1992-10-01 Synergen, Inc. Pegylation of polypeptides
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DK0669986T3 (da) 1992-11-13 2003-07-28 Idec Pharma Corp Fuldstændigt inaktiverede kozac-sekvenser til ekspression i pattedyr
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
JP4128227B2 (ja) 1997-03-14 2008-07-30 バイオジェン・アイデック・インコーポレイテッド 哺乳類細胞内の特定部位に相同組換えによって遺伝子を組み込む方法とそれを実施するためのベクター
EP2267026A1 (en) 2000-04-12 2010-12-29 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002226028A1 (en) 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
PL369065A1 (en) 2001-09-04 2005-04-18 Merck Patent Gmbh Modified factor ix
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
KR101271635B1 (ko) 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
EP2371856B1 (en) 2004-11-12 2022-05-18 Bayer HealthCare LLC Site-directed modification of FVIII
MX2008001865A (es) 2005-08-12 2008-04-15 Human Genome Sciences Inc Proteinas de fusion de albumina.
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
EP2423307A1 (en) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IV polypeptides and use thereof for treatment
US20100254944A1 (en) 2006-09-14 2010-10-07 Mani Subramanian Albumin Fusion Proteins
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
NZ580670A (en) 2007-06-21 2011-09-30 Univ Muenchen Tech Biological active proteins having increased in vivo and/or vitro stability
CN102026653B (zh) 2007-10-15 2014-06-18 北卡罗来纳-查佩尔山大学 半衰期延长的人因子ⅸ变体
WO2009137254A2 (en) 2008-04-16 2009-11-12 Bayer Healthcare Llc Modified factor ix polypeptides and uses thereof
CA2721362A1 (en) 2008-04-16 2009-11-19 Bayer Healthcare Llc Site-directed modification of factor ix
TWI573806B (zh) 2008-04-17 2017-03-11 巴克斯歐塔公司 生物活性胜肽
EP2268807A2 (en) 2008-04-21 2011-01-05 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
EP2393828B1 (en) 2009-02-03 2016-10-12 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
EP2440228B8 (en) 2009-06-08 2023-02-22 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
MX354555B (es) 2009-06-08 2018-03-09 Amunix Operating Inc Polipeptidos de la hormona de crecimiento y metodos de preparacion y su uso.
WO2011028229A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
EP4382170A2 (en) 2009-12-06 2024-06-12 Bioverativ Therapeutics Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
AU2011274423B2 (en) 2010-07-09 2016-02-11 Bioverativ Therapeutics Inc. Chimeric clotting factors
MX356527B (es) 2010-07-09 2018-06-01 Bioverativ Therapeutics Inc Polipeptidos de factor ix y metodos para usarlos.
EP3508573A1 (en) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
LT2882450T (lt) 2012-07-11 2020-03-25 Bioverativ Therapeutics Inc. Faktoriaus viii komplekso su xten ir von vilebrando faktoriumi baltymas ir jo panaudojimas
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
EP3331608A4 (en) * 2015-08-03 2019-05-01 Bioverativ Therapeutics Inc. FUSION XI FUSION PROTEINS AND METHODS OF MAKING AND USING THE SAME

Also Published As

Publication number Publication date
MA47416A (fr) 2019-12-11
WO2018144623A1 (en) 2018-08-09
CR20190389A (es) 2019-11-26
AR110871A1 (es) 2019-05-08
BR112019015569A2 (pt) 2020-03-17
MX2019009063A (es) 2019-10-21
EA201991768A1 (ru) 2020-01-22
AU2018215092A1 (en) 2019-08-29
CA3051862A1 (en) 2018-08-09
TW201831521A (zh) 2018-09-01
IL268234A (en) 2019-09-26
KR20190112763A (ko) 2019-10-07
US20210238259A1 (en) 2021-08-05
SG11201906788XA (en) 2019-08-27
JP2020505424A (ja) 2020-02-20
PH12019501765A1 (en) 2020-03-16
CN110831613A (zh) 2020-02-21
EP3576762A1 (en) 2019-12-11

Similar Documents

Publication Publication Date Title
CL2018000302A1 (es) Proteínas de fusión de factor ix y métodos para producirlas y utilizarlas
CO2020006900A2 (es) Medios y método para preparar vectores virales y usos de los mismos
CO2019003154A2 (es) Anticuerpos anti-pd-1 y sus usos
CO2018005369A2 (es) Inhibidores triazol de acc y usos de los mismos
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
CL2018000358A1 (es) Proteínas de fusión de gitrl y usos de las mismas
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
CR20160141A (es) Formulaciones de anticuerpos anti-pdl1
MX2019007021A (es) Anticuerpos il-11ra.
DOP2018000258A (es) Anticuerpos anti-cd40 y sus usos
CR20150482A (es) Anticuerpos e inmunoconjugados anti-b7-h4
BR112017009374A2 (pt) ?composições de ramnolipídeo de baixa viscosidade concentradas?
UY34617A (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas
BR112017025711A2 (pt) ?composições, processo para preparação de siloxanos modificados por poliéter e uso das composições inovadoras?
CL2017001227A1 (es) Ganado lechero híbrido y sistemas para maximizar la ventaja híbrida.
CL2019002251A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos.
BR112018001814A2 (pt) unidade móvel de produção de implante
CY1122644T1 (el) Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων
BR112017009792A2 (pt) anticorpos anti-pdgf-b e métodos de uso
BR112017014598A2 (pt) métodos e usos para hidrólise de queratina
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
UY35463A (es) Formulaciones de polipéptido fc-factor ix.
CL2019002155A1 (es) Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas.
MX2017009180A (es) Biomateriales de nanocelulosa sintetizada bacterialmente y de fases múltiples, y método para producirlos.
BR112018077458A2 (pt) proteases aspárticas